PE20061434A1 - MULTIVALENT HPV VACCINE - Google Patents

MULTIVALENT HPV VACCINE

Info

Publication number
PE20061434A1
PE20061434A1 PE2006000425A PE2006000425A PE20061434A1 PE 20061434 A1 PE20061434 A1 PE 20061434A1 PE 2006000425 A PE2006000425 A PE 2006000425A PE 2006000425 A PE2006000425 A PE 2006000425A PE 20061434 A1 PE20061434 A1 PE 20061434A1
Authority
PE
Peru
Prior art keywords
hpv
vaccine
psv
proteins
refers
Prior art date
Application number
PE2006000425A
Other languages
Spanish (es)
Inventor
Gary Dubin
Bruce Innins
Martine Cecile Wettendorff
Moncef Mohammed Slaoui
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Priority claimed from US11/367,601 external-priority patent/US7858098B2/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20061434A1 publication Critical patent/PE20061434A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA VACUNA MULTIVALENTE DE PAPILOMAVIRUS HUMANO (VPH) QUE COMPRENDE: A) PROTEINAS L1 O FRAGMENTOS INMUNOGENICOS DE LAS MISMAS DE VPH-16 Y VPH 18 Y AL MENOS OTRO TIPO ONCOGENICO DE VPH TAL COMO VPH-33, VPH-58 O VPH-59; SIENDO OMITIDOS LOS TIPOS VPH-31, VPH-45 Y VPH-52. EN DICHA VACUNA LA PROTEINA L1 DE VPH O FRAGMENTOS DE LA MISMA SE ENCUENTRA EN FORMA DE UN CAPSOMERO O PARTICULA SEMEJANTE AL VIRUS (PSV), Y AL MENOS UNA DE LAS PROTEINAS L1 ES UNA L1 TRUNCADA DONDE LA CANTIDAD DE VACUNA VARIA CON EL NUMERO DE TIPOS DE PSV EN UNA CANTIDAD COMPRENDIDA ENTRE 1 A 100 UG DE CADA PSV Y B) UN ADYUVANTE TALES COMO HIDROXIDO DE ALUMINIO, UNA EMULSION DE ACEITE EN AGUA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE FABRICACION. DICHA VACUNA PROPORCIONA PROTECCION CRUZADA CONTRA LA INFECCION CAUSADA POR EL TIPO DE VPH OMITIDOREFERS TO A MULTIVALENT VACCINE OF HUMAN PAPILLOMAVIRUS (HPV) THAT INCLUDES: A) L1 PROTEINS OR IMMUNOGENIC FRAGMENTS OF THE SAME OF HPV-16 AND HPV 18 AND AT LEAST ANOTHER ONCOGENIC TYPE OF HPV, SUCH AS HPV-33 HPV-59; THE HPV-31, HPV-45 AND HPV-52 TYPES ARE OMITTED. IN SUCH VACCINE, HPV L1 PROTEIN OR FRAGMENTS OF IT IS IN THE FORM OF A CAPSOMER OR VIRUS-LIKE PARTICLE (PSV), AND AT LEAST ONE OF THE L1 PROTEINS IS A TRUNCATED L1 WHERE THE NUMBER OF VACCINE VARIES OF TYPES OF PSV IN A QUANTITY INCLUDED BETWEEN 1 TO 100 UG OF EACH PSV AND B) AN ADJUVANT SUCH AS ALUMINUM HYDROXIDE, AN EMULSION OF OIL IN WATER. IT ALSO REFERS TO A MANUFACTURING PROCEDURE. SUCH VACCINE PROVIDES CROSS PROTECTION AGAINST INFECTION CAUSED BY THE MISSED TYPE OF HPV

PE2006000425A 2005-04-26 2006-04-24 MULTIVALENT HPV VACCINE PE20061434A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US11/367,601 US7858098B2 (en) 2002-12-20 2005-12-16 Vaccine

Publications (1)

Publication Number Publication Date
PE20061434A1 true PE20061434A1 (en) 2007-01-26

Family

ID=42334365

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000425A PE20061434A1 (en) 2005-04-26 2006-04-24 MULTIVALENT HPV VACCINE

Country Status (3)

Country Link
IL (1) IL186591A0 (en)
MA (1) MA29679B1 (en)
PE (1) PE20061434A1 (en)

Also Published As

Publication number Publication date
IL186591A0 (en) 2008-01-20
MA29679B1 (en) 2008-08-01

Similar Documents

Publication Publication Date Title
NO2018010I1 (en) HPV 31 L1 protein
ECSP055869A (en) HPV-16 AND -18 L1 VLP VACCINE
EA201190327A1 (en) NEW CONSTRUCTIONS OF HUMAN PAPILLOMA VIRUS PROTECTION (HPV) AND THEIR APPLICATION IN THE PREVENTION OF DISEASE CAUSED BY HPV
TW200519203A (en) Optimized expression of HPV 58 L1 in yeast
AR077396A2 (en) OPTIMIZED EXPRESSION OF THE L1 CAPSIDE PROTEIN OF THE VPH45 HUMAN PAPILOMA VIRUS IN LEAVES
ES2263406T1 (en) PRODUCTION OF CAPSIDA L1 PROTEIN AND HUMAN PAPILOMAVIRUS VIRUS TYPE VIRUS PARTICLES HBV-11.
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
EP2708549A3 (en) Improved vaccines and methods for using the same
DK1968632T3 (en) Improved influenza vaccine
WO2007121895A3 (en) Hpv-16-based papillomavirus vaccine
MX2020011299A (en) Improved vaccines for human papilloma virus and methods for using the same.
RU2017139870A (en) NEW NPR-B AGONISTS
JP2006512413A5 (en)
BR112018011310A2 (en) A mutant of human papillomavirus type 58 L1 protein
JP2015504897A5 (en)
DE602005019238D1 (en) OTEINEN
AR054259A1 (en) VACCINE AGAINST HUMAN PAPILOMA VIRUS (HPV)
BR112018011331A2 (en) human papillomavirus l1 protein mutant type 11
JP2008539184A5 (en)
PE20230349A1 (en) VACCINES FOR RECURRENT RESPIRATORY PAPILLOMATOSIS AND METHODS OF USING THESE
PE20061434A1 (en) MULTIVALENT HPV VACCINE
CO5580837A2 (en) DNA VACCINE CODING AT LEAST TWO NON-STRUCTURAL EARLY PROTEINS OF PAPILOMAVIRUS
PE20061320A1 (en) VACCINE AGAINST HUMAN PAPILLOMA VIRUS (HPV)
JP2008539182A5 (en)

Legal Events

Date Code Title Description
FC Refusal